Your browser doesn't support javascript.
loading
[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. / Critères de non-qualification des donneurs des cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Boiron, Jean-Michel; Garban, Frédéric; Audat, Françoise; Ader, Virginie; Andreu, Heidrun; Aubrège-Bouvier, Christine; Borel, Cécile; Huynh, Phuong; Nacimento, Francisca; Yakoub-Agha, Ibrahim; Chabannon, Christian.
Afiliación
  • Boiron JM; Université de Bordeaux, hématologie-transfusion, expert près la cour d'appel de bordeaux, UFR médecine, Inserm U1034, 1, avenue de Magellan, 33600 Pessac, France. Electronic address: jean-michel.boiron@u-bordeaux.fr.
  • Garban F; Université de Grenoble-Alpes, CHU Grenoble-Alpes, expert près la cour d'appel de Grenoble et près la cour administrative d'appel de Lyon, ABM et unité transfusion, Lyon, France.
  • Audat F; Agence de la biomédecine, direction générale médicale et scientifique, direction prélèvements/greffes CSH, pôle stratégie prélèvements greffes CSH, 1, avenue du Stade de France, 93212 Saint-Denis-la-Plaine cedex, France.
  • Ader V; Centre de santé, site EFS de Lille, EFS Nord de France, 38, avenue charles-saint-venant, 59800 Lille, France.
  • Andreu H; Hôpital Jacques-Monod-Le-Havre, centre de santé, site EFS du Havre, 29, avenue Mendès-France, 76290 Montivilliers, Normandie.
  • Aubrège-Bouvier C; Service de délivrance, site EFS de St-Priest-en-Jarez, 108, avenue Albert-Raimond, 42277 Saint-Priest-en-Jarez, France; Centre de santé site EFS de St-Priest-en-Jarez, 108, avenue Albert-Raimond, 42277 Saint-Priest-en-Jarez, France.
  • Borel C; Service d'hématologie du Pr Récher, institut universitaire du cancer de Toulouse, site Oncopôle, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.
  • Huynh P; Hematology Department, institut Jules-Bordet, Apheresis Unit, rue Héger-Bordet 1, 1000 Bruxelles, France.
  • Nacimento F; CHU de Réunion, service de thérapie cellulaire et tissulaire, site Sud (Terre Sainte), BP 350, 97448 Saint-Pierre, Réunion.
  • Yakoub-Agha I; Université de Lille 2, CHU de Lille, LIRIC Inserm U995, 59000 Lille, France.
  • Chabannon C; Aix-Marseille université, département de biologie du cancer, département d'oncohematologie, institut Paoli-Calmettes, centre de thérapie cellulaire, centre de lutte contre le cancer, unité de transplantation et de thérapie cellulaire, Inserm CBT-1409, 232, boulevard Sainte-Marguerite, 13273 Marseill
Bull Cancer ; 104(12S): S76-S83, 2017 Dec.
Article en Fr | MEDLINE | ID: mdl-29173975
ABSTRACT
The evolution of HLA typing and transplantation techniques makes it easier to identify a donor for hematopoietic stem cell (HSC) transplantation. This activity, strongly regulated by regulatory or normative texts, implies in addition biological, medical, para-medical and sometimes psychological evaluations. The benefit/risk discussion is complicated because it must take into account the benefit/risk ratio for the recipient, and the donor risk. No Evidence-Based Medicine data is available and serious events are very rare situations. Biovigilance declarations and their analysis are of fundamental importance. Certain obvious and definite contraindications could be detected very early in the process. It is important to assess whether a risk factor or pathology contributes to increasing the risk associated with collection. In case of recipient risk, the situation should be discussed with the patient team. These recommendations focus on adult peripheral blood HSC donors. They refer to donor information, confidentiality of exchanges, the impact of moral or material pressures, declarations of biovigilance, collegiality and traceability of difficult decisions, desirable experience and training for doctors in charge, use of expert advice informed by an explicit exchange on the possible risks, parsimony of therapeutic interventions and minimization of risks for the donor. We also recommend creation, availability and use by the community of tools and documents (registries, questionnaires, synthetic recommendations, feedback, and collegial qualification meetings) useful for practice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre Hematopoyéticas / Prueba de Histocompatibilidad / Donadores Vivos Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans País/Región como asunto: Europa Idioma: Fr Revista: Bull Cancer Año: 2017 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Madre Hematopoyéticas / Prueba de Histocompatibilidad / Donadores Vivos Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Humans País/Región como asunto: Europa Idioma: Fr Revista: Bull Cancer Año: 2017 Tipo del documento: Article